× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

more details ...

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Interactive explorer of NMA results

2Clemency, 2021 Ezer N (CONTAIN), 20211PINETREE (GS-US-540-9012), 20213C3PO, 2020 CONV-ERT, 2021 CoV-Early (Gharbharan), 20222Cov-2067 Weinreich (1200mg) Cohort 1, 2020 Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021casirivimab/imdevimab (Ronapreve) vs. control 0.54 [0.08; 3.54]0.54 [0.08;3.54]casirivimab/imdevimab (Ronapreve) vs. control 0.54 [0.08; 3.54]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 0.37 [0.03; 4.05]0.37 [0.03;4.05]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 0.37 [0.03; 4.05]casirivimab/imdevimab (Ronapreve) vs. corticosteroids 0.55 [0.02; 15.71]0.55 [0.02;15.71]casirivimab/imdevimab (Ronapreve) vs. corticosteroids 0.55 [0.02; 15.71]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.53 [0.01; 41.14]0.53 [0.01;41.14]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.53 [0.01; 41.14]control vs. casirivimab/imdevimab (Ronapreve) 1.86 [0.28; 12.26]1.86 [0.28;12.26]control vs. casirivimab/imdevimab (Ronapreve) 1.86 [0.28; 12.26]control vs. convalescent plasma treatment 0.69 [0.16; 3.02]0.69 [0.16;3.02]control vs. convalescent plasma treatment 0.69 [0.16; 3.02]control vs. corticosteroids 1.02 [0.06; 16.39]1.02 [0.06;16.39]control vs. corticosteroids 1.02 [0.06; 16.39]control vs. remdesivir 0.99 [0.02; 49.86]0.99 [0.02;49.86]control vs. remdesivir 0.99 [0.02; 49.86]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 2.71 [0.25; 29.86]2.71 [0.25;29.86]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 2.71 [0.25; 29.86]convalescent plasma treatment vs. control 1.46 [0.33; 6.42]1.46 [0.33;6.42]convalescent plasma treatment vs. control 1.46 [0.33; 6.42]convalescent plasma treatment vs. corticosteroids 1.49 [0.06; 34.62]1.49 [0.06;34.62]convalescent plasma treatment vs. corticosteroids 1.49 [0.06; 34.62]convalescent plasma treatment vs. remdesivir 1.44 [0.02; 95.29]1.44 [0.02;95.29]convalescent plasma treatment vs. remdesivir 1.44 [0.02; 95.29]corticosteroids vs. casirivimab/imdevimab (Ronapreve) 1.83 [0.06; 52.36]1.83 [0.06;52.36]corticosteroids vs. casirivimab/imdevimab (Ronapreve) 1.83 [0.06; 52.36]corticosteroids vs. control 0.98 [0.06; 15.76]0.98 [0.06;15.76]corticosteroids vs. control 0.98 [0.06; 15.76]corticosteroids vs. convalescent plasma treatment 0.67 [0.03; 15.66]0.67 [0.03;15.66]corticosteroids vs. convalescent plasma treatment 0.67 [0.03; 15.66]corticosteroids vs. remdesivir 0.97 [0.01; 118.26]0.97 [0.01;118.26]corticosteroids vs. remdesivir 0.97 [0.01; 118.26]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.89 [0.02; 146.71]1.89 [0.02;146.71]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.89 [0.02; 146.71]remdesivir vs. control 1.01 [0.02; 51.30]1.01 [0.02;51.30]remdesivir vs. control 1.01 [0.02; 51.30]remdesivir vs. convalescent plasma treatment 0.70 [0.01; 46.12]0.70 [0.01;46.12]remdesivir vs. convalescent plasma treatment 0.70 [0.01; 46.12]remdesivir vs. corticosteroids 1.03 [0.01; 126.54]1.03 [0.01;126.54]remdesivir vs. corticosteroids 1.03 [0.01; 126.54]Risk of bias: - high: 0.0 % - some concerns: 50.0 % - low: 50.0 % - NA: 0.0 %corticosteroidsRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %remdesivirRisk of bias: - high: 0.0 % - some concerns: 33.3 % - low: 66.7 % - NA: 0.0 %convalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %casirivimab/imdevimab (Ronapreve)Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNinterferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---0.97
0.01; 118.26		0.67
0.03; 15.66		NANA1.83
0.06; 52.36		NANANA0.98
0.06; 15.76
remdesivir1.03
0.01; 126.54		---0.70
0.01; 46.12		NANA1.89
0.02; 146.71		NANANA1.01
0.02; 51.30
convalescent plasma treatment1.49
0.06; 34.62		1.44
0.02; 95.29		---NANA2.71
0.25; 29.86		NANANA1.46
0.33; 6.42
baricitinibNANANA---NANANANANANA
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)0.55
0.02; 15.71		0.53
0.01; 41.14		0.37
0.03; 4.05		NANA---NANANA0.54
0.08; 3.54
interferonNANANANANANA---NANANA
tocilizumab NANANANANANANA---NANA
sarilumabNANANANANANANANA---NA
control1.02
0.06; 16.39		0.99
0.02; 49.86		0.69
0.16; 3.02		NANA1.86
0.28; 12.26		NANANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons